The prolyl hydroxylation of hypoxia-inducible factor 1α (HIF-1α) mediated by the EGLN–
pVHL pathway represents a classic signalling mechanism that mediates cellular adaptation …

The Bromo-and Extra-Terminal (BET) proteins BRD2, BRD3, and BRD4 play important roles
in transcriptional regulation, epigenetics, and cancer and are the targets of pan-BET …

Targeting protein degradation with Proteolysis-Targeting Chimeras (PROTACs) is an area of
great current interest in drug discovery. Nevertheless, although the high effectiveness of …

Methods to direct the degradation of protein targets with proximity-inducing molecules that
coopt the cellular degradation machinery are advancing in leaps and bounds, and diverse …

Although proteolysis targeting chimeras (PROTACs) have become promising therapeutic
modalities, important concerns exist about the potential toxicity of the approach owing to …

Immunomodulatory drugs bind to cereblon (CRBN) to confer differentiated substrate
specificity on the CRL4CRBN E3 ubiquitin ligase. Here we report the identification of a new …

Hypoxia and inflammation are frequently co-incidental features of the tissue
microenvironment in a wide range of inflammatory diseases. While the impact of hypoxia on …

Traditional pharmaceutical drug discovery is almost exclusively focused on directly
controlling protein activity to cure diseases. Modulators of protein activity, especially …

Abstract Since the Von Hippel–Lindau (VHL) disease tumour suppressor gene VHL was
identified in 1993 as the genetic basis for a rare disorder, it has proved to be of wide medical …

A classic physiologic response to systemic hypoxia is the increase in red blood cell
production. Hypoxia-inducible factors (HIFs) orchestrate this response by inducing cell-type …